Systematic review of hypofractionated radiation therapy for prostate cancer

Nicholas G. Zaorsky, Nitin Ohri, Timothy N. Showalter, Adam P. Dicker, Robert B. Den

Research output: Contribution to journalReview articlepeer-review

53 Scopus citations


Prostate cancer is the second most prevalent solid tumor diagnosed in men in the United States and Western Europe. Conventionally fractionated external beam radiation therapy (1.8-2.0. Gy/fraction) is an established treatment modality for men in all disease risk groups. Emerging evidence from experimental and clinical studies suggests that the α/β ratio for prostate cancer may be as low as 1.5. Gy, which has prompted investigators around the world to explore moderately hypofractionated radiation therapy (2.1-3.5. Gy/fraction). We review the impetus behind moderate hypofractionation and the current clinical evidence supporting moderate hypofractionated radiation therapy for prostate cancer. Although hypofractionated radiation therapy has many theoretical advantages, there is no clear evidence from prospective, randomized, controlled trials showing that hypofractionated schedules have improved outcomes or lower toxicity than conventionally fractionated regimens. Currently, hypofractionated schedules should only be used in the context of clinical trials. High dose rate brachytherapy and stereotactic body radiation therapy (fraction size 3.5. Gy and greater) are alternative approaches to hypofractionation, but are beyond the scope of this report.

Original languageEnglish (US)
Pages (from-to)728-736
Number of pages9
JournalCancer Treatment Reviews
Issue number7
StatePublished - Nov 2013

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Systematic review of hypofractionated radiation therapy for prostate cancer'. Together they form a unique fingerprint.

Cite this